Your browser is no longer supported. Please, upgrade your browser.
APLS Apellis Pharmaceuticals, Inc. monthly Stock Chart
APLS [NASD]
Apellis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.31 Insider Own2.40% Shs Outstand75.63M Perf Week15.39%
Market Cap3.29B Forward P/E- EPS next Y-6.43 Insider Trans-3.08% Shs Float59.25M Perf Month32.74%
Income-536.40M PEG- EPS next Q-1.06 Inst Own82.90% Short Float17.20% Perf Quarter71.16%
Sales0.60M P/S5489.07 EPS this Y-108.90% Inst Trans0.90% Short Ratio17.13 Perf Half Y39.75%
Book/sh1.40 P/B34.00 EPS next Y2.00% ROA-79.00% Target Price52.79 Perf Year69.52%
Cash/sh10.52 P/C4.52 EPS next 5Y2.80% ROE-339.90% 52W Range16.85 - 49.36 Perf YTD55.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-3.57% Beta-
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low182.49% ATR2.79
Employees235 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)80.95 Volatility8.36% 8.00%
OptionableYes Debt/Eq0.00 EPS Q/Q-63.80% Profit Margin- Rel Volume1.22 Prev Close47.85
ShortableYes LT Debt/Eq3.34 EarningsNov 03 Payout- Avg Volume594.93K Price47.60
Recom1.80 SMA2026.67% SMA5036.95% SMA20048.31% Volume722,589 Change-0.52%
Nov-19-20Initiated Needham Buy $59
Sep-01-20Initiated Stifel Buy $40
Jul-20-20Initiated ROTH Capital Buy $50
Jun-17-20Initiated BTIG Research Neutral
Apr-01-20Initiated Raymond James Strong Buy $86
Mar-31-20Initiated BMO Capital Markets Outperform $54
Mar-11-20Upgrade Wedbush Underperform → Neutral $29
Jan-07-20Initiated SVB Leerink Mkt Perform $30
Dec-19-19Initiated BofA/Merrill Buy $36
Nov-22-19Initiated Wedbush Underperform
Nov-05-19Initiated Credit Suisse Neutral $33
Aug-01-19Reiterated Cantor Fitzgerald Overweight $52 → $50
Jul-12-19Upgrade JP Morgan Neutral → Overweight $35 → $49
Mar-29-19Initiated Robert W. Baird Outperform $45
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Jul-30-18Upgrade B. Riley FBR Neutral → Buy $27
May-24-18Initiated Cantor Fitzgerald Overweight $52
Apr-12-18Downgrade B. Riley FBR, Inc. Buy → Neutral $27
Feb-08-18Initiated B. Riley FBR, Inc. Buy $27
Nov-20-20 12:05PM  
Nov-19-20 06:45AM  
Nov-17-20 10:07AM  
Nov-16-20 07:00AM  
Nov-13-20 10:40AM  
Nov-11-20 07:00AM  
Nov-05-20 07:00AM  
Nov-03-20 10:29AM  
05:27AM  
Nov-02-20 07:00AM  
Oct-27-20 10:22AM  
07:00AM  
Oct-19-20 07:00AM  
Oct-15-20 07:00AM  
Oct-09-20 10:14AM  
Oct-07-20 04:05PM  
Oct-05-20 07:00AM  
Oct-03-20 11:05AM  
Sep-24-20 04:05PM  
Sep-21-20 04:05PM  
Sep-16-20 03:25PM  
09:43AM  
Sep-15-20 07:00AM  
Sep-04-20 04:05PM  
Sep-02-20 07:00AM  
Sep-01-20 09:47AM  
Aug-30-20 11:30AM  
Aug-21-20 04:05PM  
Aug-07-20 04:05PM  
Jul-31-20 07:00AM  
Jul-13-20 10:31AM  
Jul-07-20 04:05PM  
07:00AM  
Jul-02-20 08:00AM  
Jun-16-20 07:00AM  
Jun-12-20 04:23PM  
09:48AM  
08:20AM  
02:30AM  
Jun-10-20 05:34PM  
Jun-05-20 04:05PM  
Jun-04-20 07:00AM  
May-29-20 04:05PM  
May-28-20 07:00AM  
May-21-20 07:00AM  
May-14-20 10:55AM  
May-08-20 07:00AM  
May-07-20 04:05PM  
07:24AM  
Apr-29-20 04:11PM  
Apr-28-20 07:00AM  
Apr-07-20 11:33AM  
10:01AM  
Apr-06-20 08:00AM  
Feb-27-20 04:44PM  
Feb-26-20 07:00AM  
Feb-06-20 01:23PM  
Jan-16-20 04:30PM  
Jan-15-20 05:39AM  
Jan-13-20 04:57PM  
12:10PM  
09:39AM  
Jan-09-20 02:18PM  
Jan-08-20 09:30PM  
10:07AM  
08:12AM  
07:48AM  
Jan-07-20 04:15PM  
04:11PM  
01:34PM  
12:02PM  
10:29AM  
10:26AM  
09:24AM  
07:00AM  
06:38AM  
Jan-02-20 07:00AM  
Dec-09-19 08:48AM  
Dec-06-19 04:11PM  
Nov-26-19 07:00AM  
Nov-15-19 05:30PM  
Nov-08-19 10:00AM  
Nov-07-19 05:30PM  
Nov-05-19 07:30AM  
Oct-28-19 09:26AM  
Oct-16-19 11:43AM  
Oct-11-19 04:01PM  
Oct-04-19 05:30PM  
Oct-03-19 08:37AM  
Sep-27-19 05:30PM  
Sep-26-19 08:00AM  
Sep-18-19 08:00AM  
Sep-16-19 05:00PM  
Sep-13-19 07:31AM  
Sep-12-19 08:22AM  
Sep-11-19 04:38PM  
Sep-09-19 05:00PM  
Sep-03-19 08:00AM  
Aug-28-19 05:00PM  
08:00AM  
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Machiels AlecDirectorNov 16Option Exercise2.672,5006,675672,044Nov 17 07:12 PM
Grossi FedericoCHIEF MEDICAL OFFICERNov 16Option Exercise3.205,75018,40033,777Nov 17 07:11 PM
Francois CedricChief Executive OfficerNov 16Sale39.385,000196,9001,078,079Nov 17 07:13 PM
Machiels AlecDirectorNov 16Sale39.382,50098,450669,544Nov 17 07:12 PM
Grossi FedericoCHIEF MEDICAL OFFICERNov 02Sale31.0960018,65427,725Nov 03 04:01 PM
Machiels AlecDirectorOct 15Option Exercise2.672,5006,675672,044Oct 16 05:56 PM
Machiels AlecDirectorOct 15Sale35.002,50087,500669,544Oct 16 05:56 PM
Francois CedricChief Executive OfficerOct 15Sale34.465,000172,3001,083,079Oct 16 05:31 PM
Brown Victoria L.Program Team LeadOct 07Option Exercise18.9812,000227,76015,607Oct 09 04:45 PM
Machiels AlecDirectorOct 07Option Exercise2.677,50020,025677,044Oct 09 04:48 PM
Machiels AlecDirectorOct 07Sale35.007,500262,500669,544Oct 09 04:48 PM
Brown Victoria L.Program Team LeadOct 07Sale35.0012,000420,0003,607Oct 09 04:45 PM
Grossi FedericoSee RemarksOct 01Sale30.2260018,13228,325Oct 02 04:14 PM
Francois CedricChief Executive OfficerSep 15Sale30.965,000154,8001,088,079Sep 16 04:03 PM
Grossi FedericoSee RemarksSep 01Sale31.5860018,94828,925Sep 02 04:36 PM
Francois CedricChief Executive OfficerAug 20Sale30.003,457103,7101,093,079Aug 21 04:36 PM
Francois CedricChief Executive OfficerAug 18Sale30.001,54346,2901,096,536Aug 20 04:45 PM
Grossi FedericoSee RemarksAug 03Sale26.2860015,76829,525Aug 05 04:37 PM
Francois CedricChief Executive OfficerJul 15Sale32.125,000160,6001,098,079Jul 16 04:07 PM
Grossi FedericoSee RemarksJul 01Sale32.4385027,56630,125Jul 02 05:48 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.